Pancreatic Cancer Research

Clinical trialPhase 2 / Phase 3Unknown

Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients

NCT05955157↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 2 / Phase 3
Status
Unknown
Study type
Interventional
Start
3 January 2023
Expected end
June 2025
Enrollment
52 participants
Sites
1
Primary outcomes
Number of participants with treatment-related adverse events; Incidence of treatment-emergent hematologic side effects
Sponsor
Other
Results posted
No
Last update
10 January 2024

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 8